Gilteritinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 40 mg
Reference Brands: Xospata (USA/India), LuciGil (Asia)
Category:
Oncology Cancer Care
Gilteritinib is available in Tablets
and strengths such as 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Gilteritinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Gilteritinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Gilteritinib is a targeted anticancer medication used in the treatment of acute myeloid leukemia (AML), one of the most common types of leukemia in adults. AML is often associated with a poor prognosis, especially in patients whose disease has relapsed or does not respond to initial treatment. A significant proportion of AML patients carry a mutation in the FMS-like tyrosine kinase 3 (FLT3) gene, which leads to increased cancer cell growth and reduced cellular differentiation, contributing to the aggressive nature of the disease.
Gilteritinib is a second-generation FLT3 inhibitor designed to specifically target and block the activity of the FLT3 receptor. By inhibiting this signaling pathway, the drug helps slow the proliferation of leukemia cells and supports better disease control. It is primarily indicated for adult patients with relapsed or refractory AML who test positive for an FLT3 mutation using an approved diagnostic test.
Approved by the U.S. Food and Drug Administration (FDA), Gilteritinib represents an important advancement in targeted therapy for AML. It is marketed under the brand name Xospata and is administered orally in tablet form. The drug has shown improved clinical outcomes compared to conventional therapies in patients with FLT3-mutated AML.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing